Article Text
Statistics from Altmetric.com
Immunisation in Alzheimer’s disease
Although immunisation with Abeta(42) resulted in clearance of amyloid plaques in patients with Alzheimer’s disease, this did not prevent progressive neurodegeneration. This was what researchers found in a randomised, placebo-controlled phase I trial which looked at the long-term effects of Abeta42 immunisation in Alzheimer’s disease. The follow-up study of this trial which they began in 2000 was completed in September, 2006. Plaques were assessed in terms of the percentage area of the cortex with Abeta immunostaining and by the histological features reflecting removal of plaque.
Lancet 2008;372:216–23.
Dimebon in Alzheimer’s disease
Dimebon, an antihistaminic, was safe, well tolerated, and significantly improved the clinical course of patients with mild-to-moderate Alzheimer’s disease, say researchers from Russia. They conducted a multicentre, randomised, double-blind, placebo-controlled study on 183 patients, which looked …
Other content recommended for you
- All you need to read in the other general journals
- Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
- Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study
- Course of low back pain among nurses: a longitudinal study across eight years
- Radiography of the lumbar spine in primary care patients with low back pain: randomised controlled trial
- Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial
- DTB Select: 1 | January 2013
- Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier
- Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis
- A phase II study of laquinimod in Crohn's disease